2024
Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
Le G, Wong S, Badulescu S, Au H, Di Vincenzo J, Gill H, Phan L, Rhee T, Ho R, Teopiz K, Kwan A, Rosenblat J, Mansur R, McIntyre R. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review. Journal Of Affective Disorders 2024, 355: 342-354. PMID: 38570038, DOI: 10.1016/j.jad.2024.03.165.Peer-Reviewed Original ResearchMeSH KeywordsDepressionDepressive Disorder, MajorHallucinogensHealthy VolunteersHumansKetamineLysergic Acid DiethylamidePsilocybinConceptsTreatment-resistant depressionLysergic acid diethylamideSerotonergic psychedelicsDepressive disorderHealthy controlsTheta powerHealthy volunteersBiomarkers predictive of responseGamma-band powerAssociated with increased theta powerSystematic reviewDissociative classDose of treatmentPredictive of responseClasses of agentsMood disordersBeta and delta bandsMDDAcid diethylamideMechanism of actionBiomarkers predictiveDepressionPatient populationModel of network connectivityResearch vistas
2022
Admissions to substance use treatment facilities for cannabis use disorder, 2000–2017: Does legalization matter?
Rhee TG, Rosenheck RA. Admissions to substance use treatment facilities for cannabis use disorder, 2000–2017: Does legalization matter? American Journal On Addictions 2022, 31: 423-432. PMID: 35368113, DOI: 10.1111/ajad.13286.Peer-Reviewed Original Research